within Pharmacolibrary.Drugs.ATC.V;

model V03AB19
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.3,
    adminDuration  = 600,
    adminMass      = 0.002,
    adminCount     = 1,
    Vd             = 0.0011,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Physostigmine is a reversible cholinesterase inhibitor that increases the level of acetylcholine in the synaptic cleft. It has been used primarily as an antidote for anticholinergic toxicity and to treat glaucoma. However, its clinical use is currently limited due to its side effects and availability of safer alternatives.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult humans; no published compartmental pharmacokinetic models with numerical values were identified in the literature as of June 2024.</p><h4>References</h4><ol><li>Ulrike Haase, Ingrid Rundshagen,[Pharmacotherapy--physostigmine administered post-operatively].,Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS,2007<a href='https://pubmed.ncbi.nlm.nih.gov/17366438/'>https://pubmed.ncbi.nlm.nih.gov/17366438/</a></li><li>B J Lukey, J H Parrish, D D Marlow, C R Clark, F R Sidell,Pharmacokinetics of physostigmine intramuscularly administered to guinea pigs.,Journal of pharmaceutical sciences,1990<a href='https://pubmed.ncbi.nlm.nih.gov/2273462/'>https://pubmed.ncbi.nlm.nih.gov/2273462/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V03AB19;
